|
US5716965A
(en)
*
|
1991-05-22 |
1998-02-10 |
Pfizer Inc. |
Substituted 3-aminoquinuclidines
|
|
AU657967B2
(en)
*
|
1991-06-20 |
1995-03-30 |
Pfizer Inc. |
Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
|
|
TW202432B
(Sortimente)
*
|
1991-06-21 |
1993-03-21 |
Pfizer |
|
|
MY110227A
(en)
*
|
1991-08-12 |
1998-03-31 |
Ciba Geigy Ag |
1-acylpiperindine compounds.
|
|
EP0919245A3
(en)
*
|
1991-09-20 |
2000-11-15 |
Glaxo Group Limited |
NK-1 receptor antagonist and a systemic antiinflammatory corticosteroid for the treatment of emesis
|
|
DK0613458T3
(da)
*
|
1991-11-12 |
1998-02-09 |
Pfizer |
Acykliske ethylendiaminderivater som substans P receptorantagonister
|
|
EP0641328B1
(en)
*
|
1992-05-18 |
2001-11-21 |
Pfizer Inc. |
Bridged aza-bicyclic derivatives as substance p antagonists
|
|
US5637699A
(en)
*
|
1992-06-29 |
1997-06-10 |
Merck & Co., Inc. |
Process for preparing morpholine tachykinin receptor antagonists
|
|
US6048859A
(en)
|
1992-06-29 |
2000-04-11 |
Merck & Co., Inc. |
Morpholine and thiomorpholine tachykinin receptor antagonists
|
|
US5719147A
(en)
*
|
1992-06-29 |
1998-02-17 |
Merck & Co., Inc. |
Morpholine and thiomorpholine tachykinin receptor antagonists
|
|
AU4396193A
(en)
*
|
1992-08-04 |
1994-03-03 |
Pfizer Inc. |
3-benzylamino-2-phenyl-piperidine derivatives as substance p receptor antagonists
|
|
GB9216911D0
(en)
*
|
1992-08-10 |
1992-09-23 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
JP2909214B2
(ja)
*
|
1992-08-19 |
1999-06-23 |
フアイザー・インコーポレイテツド |
置換ベンジルアミノ窒素含有非芳香族複素環化合物
|
|
US5387595A
(en)
*
|
1992-08-26 |
1995-02-07 |
Merck & Co., Inc. |
Alicyclic compounds as tachykinin receptor antagonists
|
|
US5344830A
(en)
*
|
1992-12-10 |
1994-09-06 |
Merck & Co., Inc. |
N,N-diacylpiperazine tachykinin antagonists
|
|
JP2722279B2
(ja)
*
|
1992-12-10 |
1998-03-04 |
ファイザー・インク. |
アミノメチレンで置換した非芳香族複素環式化合物及びサブスタンスpのアンタゴニストとしての使用
|
|
US5830854A
(en)
*
|
1992-12-14 |
1998-11-03 |
Merck Sharp & Dohme, Limited |
Method of treating cystic fibrosis using a tachykinin receptor antagonist
|
|
US5340826A
(en)
*
|
1993-02-04 |
1994-08-23 |
Pfizer Inc. |
Pharmaceutical agents for treatment of urinary incontinence
|
|
US5393762A
(en)
*
|
1993-06-04 |
1995-02-28 |
Pfizer Inc. |
Pharmaceutical agents for treatment of emesis
|
|
US5854262A
(en)
*
|
1993-10-07 |
1998-12-29 |
Pfizer Inc. |
Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
|
|
US5610165A
(en)
*
|
1994-02-17 |
1997-03-11 |
Merck & Co., Inc. |
N-acylpiperidine tachykinin antagonists
|
|
IL112778A0
(en)
*
|
1994-03-04 |
1995-05-26 |
Merck & Co Inc |
Substituted heterocycles, their preparation and pharmaceutical compositions containing them
|
|
TW397825B
(en)
*
|
1994-10-14 |
2000-07-11 |
Novartis Ag |
Aroyl-piperidine derivatives
|
|
FR2725900B1
(fr)
*
|
1994-10-21 |
1997-07-18 |
Sanofi Sa |
Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice
|
|
TW458774B
(en)
|
1995-10-20 |
2001-10-11 |
Pfizer |
Antiemetic pharmaceutical compositions
|
|
CA2251368A1
(en)
*
|
1997-02-14 |
1998-08-20 |
Bayer Corporation |
Amide derivatives as selective neuropeptide y receptor antagonists
|
|
US6245817B1
(en)
|
1997-02-14 |
2001-06-12 |
Bayer Corporation |
NPY5 receptor antagonists and methods for using same
|
|
US6048900A
(en)
*
|
1998-02-13 |
2000-04-11 |
Bayer Corporation |
Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
|
|
CA2251580A1
(en)
*
|
1997-02-14 |
1998-08-20 |
Bayer Corporation |
Amides as npy5 receptor antagonists
|
|
CN1414953A
(zh)
|
1999-11-03 |
2003-04-30 |
阿尔巴尼分子研究公司 |
芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和5-羟色胺重摄取的用途
|
|
US7163949B1
(en)
|
1999-11-03 |
2007-01-16 |
Amr Technology, Inc. |
4-phenyl substituted tetrahydroisoquinolines and use thereof
|
|
US7119207B2
(en)
|
2000-04-10 |
2006-10-10 |
Pfizer Inc |
Benzoamide piperidine containing compounds and related compounds
|
|
JP4001486B2
(ja)
*
|
2000-04-10 |
2007-10-31 |
ファイザー・プロダクツ・インク |
ベンゾアミドピペリジン含有化合物及び関連化合物
|
|
CA2415532C
(en)
|
2000-07-11 |
2010-05-11 |
Albany Molecular Research, Inc. |
Novel 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
|
|
AU2002211621A1
(en)
*
|
2000-10-10 |
2002-04-22 |
Calyx Therapeutics, Inc. |
Tricyclic compounds and uses thereof
|
|
CN101119969B
(zh)
|
2004-07-15 |
2014-04-09 |
阿尔巴尼分子研究公司 |
芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用
|
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
|
DE102005027168A1
(de)
*
|
2005-06-13 |
2006-12-14 |
Merck Patent Gmbh |
Tetrahydrochinoline
|
|
US7956050B2
(en)
|
2005-07-15 |
2011-06-07 |
Albany Molecular Research, Inc. |
Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
|
AU2006297443B2
(en)
|
2005-09-29 |
2010-08-12 |
Merck Sharp & Dohme Corp. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
GB0617867D0
(en)
*
|
2006-09-11 |
2006-10-18 |
Glaxo Group Ltd |
Chemical compounds
|
|
CA2770486C
(en)
|
2006-09-22 |
2014-07-15 |
Merck Sharp & Dohme Corp. |
Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
|
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
|
PL2805945T3
(pl)
|
2007-01-10 |
2019-09-30 |
Msd Italia S.R.L. |
Indazole podstawione grupą amidową jako inhibitory polimerazy poli(adp-rybozy) - (parp)
|
|
CN101641099A
(zh)
|
2007-01-24 |
2010-02-03 |
葛兰素集团有限公司 |
包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
|
|
JP5319518B2
(ja)
|
2007-04-02 |
2013-10-16 |
Msd株式会社 |
インドールジオン誘導体
|
|
WO2009002495A1
(en)
|
2007-06-27 |
2008-12-31 |
Merck & Co., Inc. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
|
GB0716573D0
(en)
*
|
2007-08-24 |
2007-10-03 |
Glaxo Group Ltd |
Chemical compounds
|
|
KR20100126467A
(ko)
|
2008-03-03 |
2010-12-01 |
타이거 파마테크 |
티로신 키나아제 억제제
|
|
GB0804326D0
(en)
*
|
2008-03-07 |
2008-04-16 |
Glaxo Group Ltd |
Novel compounds
|
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
|
AR071997A1
(es)
|
2008-06-04 |
2010-07-28 |
Bristol Myers Squibb Co |
Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
|
|
UA105182C2
(ru)
|
2008-07-03 |
2014-04-25 |
Ньюрексон, Інк. |
Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
|
|
EP2413932A4
(en)
|
2009-04-01 |
2012-09-19 |
Merck Sharp & Dohme |
HAMMER OF ACT ACTIVITY
|
|
JP2012526823A
(ja)
|
2009-05-12 |
2012-11-01 |
アルバニー モレキュラー リサーチ, インコーポレイテッド |
アリール、ヘテロアリール、および複素環置換テトラヒドロイソキノリンならびにそれらの使用
|
|
JP5764553B2
(ja)
|
2009-05-12 |
2015-08-19 |
アルバニー モレキュラー リサーチ, インコーポレイテッド |
7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンおよびその使用
|
|
JP5739415B2
(ja)
|
2009-05-12 |
2015-06-24 |
ブリストル−マイヤーズ スクウィブ カンパニー |
(S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用
|
|
EP2488028B1
(en)
|
2009-10-14 |
2020-08-19 |
Merck Sharp & Dohme Corp. |
Substituted piperidines that increase p53 activity and the uses thereof
|
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
|
WO2012018754A2
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
HUE044815T2
(hu)
|
2010-08-17 |
2019-11-28 |
Sirna Therapeutics Inc |
Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
|
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
|
US8946216B2
(en)
|
2010-09-01 |
2015-02-03 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
|
EP2699568A1
(en)
|
2011-04-21 |
2014-02-26 |
Piramal Enterprises Limited |
A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
|
EP2770987B1
(en)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
|
WO2013165816A2
(en)
|
2012-05-02 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
|
RU2660429C2
(ru)
|
2012-09-28 |
2018-07-06 |
Мерк Шарп И Доум Корп. |
Новые соединения, которые являются ингибиторами erk
|
|
US20140206667A1
(en)
|
2012-11-14 |
2014-07-24 |
Michela Gallagher |
Methods and compositions for treating schizophrenia
|
|
PL2925888T3
(pl)
|
2012-11-28 |
2018-03-30 |
Merck Sharp & Dohme Corp. |
Kompozycje i sposoby do stosowania w leczeniu nowotworów
|
|
RU2690663C2
(ru)
|
2012-12-20 |
2019-06-05 |
Мерк Шарп И Доум Корп. |
Замещенные имидазопиридины в качестве ингибиторов hdm2
|
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
CN104610146A
(zh)
*
|
2015-01-23 |
2015-05-13 |
常州大学 |
一种3-氮杂二环[5,1,0]-7-醛及合成方法
|
|
CN105330588B
(zh)
*
|
2015-10-16 |
2017-09-26 |
辽宁中医药大学 |
马齿苋中生物碱Oleracone及其提取分离方法
|
|
WO2018071283A1
(en)
|
2016-10-12 |
2018-04-19 |
Merck Sharp & Dohme Corp. |
Kdm5 inhibitors
|
|
WO2019094312A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
|
AU2019317549A1
(en)
|
2018-08-07 |
2021-02-25 |
Msd International Gmbh |
PRMT5 inhibitors
|
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
EP3833667B1
(en)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
CN113121427B
(zh)
*
|
2021-03-19 |
2022-04-01 |
广东工业大学 |
一种喹啉类衍生物及其制备方法和应用
|